Improving detection of tumor cells in cutaneous T-cell lymphoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This project focuses on identifying and quantifying circulating tumor cells in patients with cutaneous T-cell lymphoma, specifically mycosis fungoides and Sézary syndrome. The study aims to develop standardized flow-cytometry techniques to enhance the accuracy and reliability of tumor cell detection in clinical settings. By designing an optimal combination of markers for spectral flow-cytometry, the researchers will assess the specificity and sensitivity of this new approach using blood samples from patients. This could lead to better diagnosis and treatment monitoring for individuals with these rare and aggressive skin lymphomas.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with cutaneous T-cell lymphoma
* Over 18 years old
* Sign the informed consent

Exclusion Criteria:

* Under 18 years old
* Do not sign the informed consent

Where it's running

• Instituto de Investigación Biomédica de Salamanca (IBSAL)
  Salamanca, Spain Recruiting

Study contacts

• Principal investigator: Julia M Almeida Parra, Prof. — Instituto de Investigación Biomédica de Salamanca
• Study coordinator: Julia M Almeida Parra, Prof.
• Email: jalmeida@usal.es
• Phone: +34 923 29 45 00

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Ruxolitinib maintenance after stem cell transplant for T‑cell lymphoma

  This phase II trial tests whether taking ruxolitinib after a stem cell transplant can lower the chance of relapse and graft‑versus‑host disease for people treated for T‑cell lymphoma.

  Recruiting at 2 sites Phase 2 Ohio State University Comprehensive Cancer Center · Columbus, Ohio and 1 other locations · NCT07356245

• Ropeginterferon treatment for cutaneous T‑cell lymphoma

  This trial tests whether ropeginterferon-alfa-2b helps people with cutaneous T‑cell lymphoma who have not responded adequately to multiple prior skin-directed therapies.

  Recruiting Phase 1 H. Lee Moffitt Cancer Center and Research Institute · Tampa, Florida · NCT07047885

• Personalized exercise and nutrition program to reduce cancer-related fatigue

  This program will try a personalized exercise and diet plan to reduce fatigue for adults with indolent lymphomas (including CLL/SLL and follicular lymphoma).

  Recruiting UNC Lineberger Comprehensive Cancer Center · Chapel Hill, North Carolina · NCT06860880

• Golidocitnib treatment for relapsed indolent T/NK-cell lymphomas

  This study is testing if a new oral medication called Golidocitnib can help people with relapsed indolent T/NK-cell lymphomas feel better after other treatments haven't worked.

  Recruiting Phase 2 Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality and 1 other locations · NCT06716658

• Tofacitinib cream for treating early-stage Cutaneous T-cell Lymphoma

  This study is testing if a new cream can help people with early-stage Cutaneous T-cell Lymphoma feel better and improve their skin after 12 weeks of treatment.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT06698822

• Systemic treatments for cutaneous T‑cell lymphoma

  This project looks at how different systemic treatments are used in adults with cutaneous T‑cell lymphoma to see which approaches are linked to longer disease control in routine care.

  Recruiting at 9 sites Fondazione Italiana Linfomi - ETS · Ancona and 17 other locations · NCT06588868

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.